Seaport Therapeutics Announces First Patient Dosed In Phase 2a Trial Of GlyphAgo In Generalized Anxiety Disorder, Expects Topline Data In Early 2028

Loading news article.

Seaport Therapeutics Announces First Patient Dosed In Phase 2a Trial Of GlyphAgo In Generalized Anxiety Disorder, Expects Topline Data In Early 2028 | WAPE

Seaport Therapeutics Announces First Patient Dosed In Phase 2a Trial Of GlyphAgo In Generalized Anxiety Disorder, Expects Topline Data In Early 2028

Article summary

Related companies

Comments —